All Stories

  1. HDL therapy today: from atherosclerosis, to stent compatibility to heart failure

    Article • Annals of Medicine, November 2019, Taylor & Francis

    Dr Massimiliano Ruscica, Prof Roberto Giovannoni

  2. Angiopoietin-like 3 and subclinical peripheral arterial disease: Evidence from the Brisighella Heart Study

    Article • European Journal of Preventive Cardiology, October 2019, SAGE Publications

    Dr Arrigo FG CICERO, Dr Massimiliano Ruscica

  3. Impact of PPAR-Alpha Polymorphisms—The Case of Metabolic Disorders and Atherosclerosis

    Article • International Journal of Molecular Sciences, September 2019, MDPI AG

    Dr Massimiliano Ruscica

  4. A NEW DAWN FOR MANAGING DYSLIPIDEMIAS: THE ERA OF RNA-BASED THERAPIES

    Article • Pharmacological Research, August 2019, Elsevier

    Dr Massimiliano Ruscica

  5. PCSK9 inhibition and inflammation: A narrative review

    Article • Atherosclerosis, July 2019, Elsevier

    Dr Massimiliano Ruscica

  6. Residual vascular risk in diabetes – Will the SPPARM alpha concept hold the key?

    Article • Diabetes & Metabolic Syndrome Clinical Research & Reviews, July 2019, Elsevier

    Dr Massimiliano Ruscica

  7. The selective peroxisome proliferator-activated receptor alpha modulator (SPPARMα) paradigm: conceptual framework and therapeutic potential

    Article • Cardiovascular Diabetology, June 2019, Springer Science + Business Media

    Dr Massimiliano Ruscica

  8. Differential effects of red yeast rice, Berberis aristata and Morus alba extracts on PCSK9 and LDL uptake

    Article • Nutrition Metabolism and Cardiovascular Diseases, June 2019, Elsevier

    Dr Massimiliano Ruscica

  9. Can we further optimize statin therapy to increase tolerability?

    Article • Expert Opinion on Drug Discovery, May 2019, Taylor & Francis

    Dr Massimiliano Ruscica

  10. PCSK9 in HIV infection: New opportunity or red herring?

    Article • Atherosclerosis, May 2019, Elsevier

    Dr Massimiliano Ruscica

  11. Efficacy and Safety of Mipomersen: A Systematic Review and Meta-Analysis of Randomized Clinical Trials

    Article • Drugs, April 2019, Springer Science + Business Media

    Dr Massimiliano Ruscica

  12. PCSK7 gene variation bridges atherogenic dyslipidemia with hepatic inflammation in NAFLD patients

    Article • Journal of Lipid Research, March 2019, American Society for Biochemistry & Molecular Biology (ASBMB)

    Dr Massimiliano Ruscica

  13. PCSK9 monoclonal antibodies and lipoprotein apheresis for lowering lipoprotein(a): making choices in an era of RNA-based therapies

    Article • European Journal of Preventive Cardiology, March 2019, SAGE Publications

    Dr Massimiliano Ruscica

  14. High-Density Lipoprotein Function Is Reduced in Patients Affected by Genetic or Idiopathic Hypogonadism

    Article • The Journal of Clinical Endocrinology & Metabolism, March 2019, Endocrine Society

    Dr Massimiliano Ruscica

  15. Deciphering the role of V200A and N291S mutations leading to LPL deficiency

    Article • Atherosclerosis, March 2019, Elsevier

    Dr Massimiliano Ruscica

  16. ETC-1002 (Bempedoic acid) for the management of hyperlipidemia: from preclinical studies to phase 3 trials

    Article • Expert Opinion on Pharmacotherapy, February 2019, Taylor & Francis

    Dr Massimiliano Ruscica, Prof. Maciej Banach

  17. Nutraceutical approach for the management of cardiovascular risk – a combination containing the probiotic Bifidobacterium longum BB536 and red yeast rice extract: results from a randomized, double-blind, placebo-controlled study

    Article • Nutrition Journal, February 2019, Springer Science + Business Media

    Dr Massimiliano Ruscica

  18. Changes in circulating pro-protein convertase subtilisin/kexin type 9 levels – experimental and clinical approaches with lipid-lowering agents

    Article • European Journal of Preventive Cardiology, February 2019, SAGE Publications

    Dr Massimiliano Ruscica

  19. Resveratrol and cognitive decline: a clinician perspective

    Article • Archives of Medical Science, January 2019, Termedia Sp. z.o.o.

    Dr Massimiliano Ruscica

  20. Long-term exposure to air pollution raises circulating levels of proprotein convertase subtilisin/kexin type 9 in obese individuals

    Article • European Journal of Preventive Cardiology, November 2018, SAGE Publications

    Dr Massimiliano Ruscica

  21. Cholesteryl ester transfer protein: An enigmatic pharmacology – Antagonists and agonists

    Article • Atherosclerosis, November 2018, Elsevier

    Dr Massimiliano Ruscica

  22. Left main coronary wall thickness correlates with the carotid intima media thickness and may provide a new marker of cardiovascular risk

    Article • European Journal of Preventive Cardiology, October 2018, SAGE Publications

    Dr Massimiliano Ruscica

  23. Serum irisin is upregulated in patients affected by amyotrophic lateral sclerosis and correlates with functional and metabolic status

    Article • Deutsche Zeitschrift für Nervenheilkunde, October 2018, Springer Science + Business Media

    Dr Massimiliano Ruscica

  24. From lipoprotein apheresis to proprotein convertase subtilisin/kexin type 9 inhibitors: Impact on low-density lipoprotein cholesterol and C-reactive protein levels in cardiovascular disease patients

    Article • European Journal of Preventive Cardiology, July 2018, SAGE Publications

    Dr Massimiliano Ruscica

  25. Lipid Lowering Drugs and Inflammatory Changes: an Impact on Cardiovascular Outcomes?

    Article • Annals of Medicine, July 2018, Taylor & Francis

    Dr Massimiliano Ruscica

  26. PCSK9 deficiency reduces insulin secretion and promotes glucose intolerance: the role of the low-density lipoprotein receptor

    Article • European Heart Journal, July 2018, Oxford University Press (OUP)

    Dr Massimiliano Ruscica

  27. Effect of statin therapy on plasma apolipoprotein CIII concentrations: A systematic review and meta-analysis of randomized controlled trials

    Article • Journal of Clinical Lipidology, May 2018, Elsevier

    Prof. Maciej Banach, Dr Massimiliano Ruscica

  28. PPAR Agonists and Metabolic Syndrome: An Established Role?

    Article • International Journal of Molecular Sciences, April 2018, MDPI AG

    Dr Massimiliano Ruscica

  29. Appropriateness of statin prescription in the elderly

    Article • European Journal of Internal Medicine, April 2018, Elsevier

    Dr Massimiliano Ruscica

  30. Influence of body variables in the development of metabolic syndrome—A long term follow-up study

    Article • PLoS ONE, February 2018, PLOS

    Dr Massimiliano Ruscica

  31. High Density Lipoproteins Inhibit Oxidative Stress-Induced Prostate Cancer Cell Proliferation

    Article • Scientific Reports, February 2018, Springer Science + Business Media

    Dr Massimiliano Ruscica

  32. PCSK9 induces a pro-inflammatory response in macrophages

    Article • Scientific Reports, February 2018, Springer Science + Business Media

    Dr Massimiliano Ruscica

  33. PCSK9 as a Positive Modulator of Platelet Activation

    Article • Journal of the American College of Cardiology, February 2018, Elsevier

    Dr Massimiliano Ruscica

  34. Present therapeutic role of cholesteryl ester transfer protein inhibitors

    Article • Pharmacological Research, February 2018, Elsevier

    Dr Massimiliano Ruscica

  35. PCSK9 antagonists and inflammation

    Article • Atherosclerosis, January 2018, Elsevier

    Dr Massimiliano Ruscica

  36. Nutraceutical approaches to metabolic syndrome

    Article • Annals of Medicine, August 2017, Taylor & Francis

    Dr Massimiliano Ruscica

  37. Bococizumab for the treatment of hypercholesterolaemia

    Article • Expert Opinion on Biological Therapy, May 2017, Taylor & Francis

    Dr Massimiliano Ruscica

  38. Translating the biology of adipokines in atherosclerosis and cardiovascular diseases: Gaps and open questions

    Article • Nutrition Metabolism and Cardiovascular Diseases, May 2017, Elsevier

    Dr Massimiliano Ruscica

  39. PPAR-α agonists are still on the rise: an update on clinical and experimental findings

    Article • Expert Opinion on Investigational Drugs, April 2017, Taylor & Francis

    Dr Massimiliano Ruscica

  40. Effect of soy on metabolic syndrome and cardiovascular risk factors: a randomized controlled trial

    Article • Zeitschrift für Ernährungswissenschaft, October 2016, Springer Science + Business Media

    Dr Massimiliano Ruscica

  41. Proprotein convertase subtilisin kexin type 9 and high-density lipoprotein metabolism: experimental animal models and clinical evidence

    Article • Translational Research, July 2016, Elsevier

    Dr Massimiliano Ruscica

  42. Increased circulating adiponectin in males with chronic HCV hepatitis

    Article • European Journal of Internal Medicine, October 2015, Elsevier

    Dr Massimiliano Ruscica

  43. Free and bound plasma leptin in anorexia nervosa patients during a refeeding program

    Article • Endocrine, April 2015, Springer Science + Business Media

    Dr Massimiliano Ruscica

  44. Menstrual and reproductive history and use of exogenous sex hormones and risk of thyroid cancer among women: a meta-analysis of prospective studies

    Article • Cancer Causes & Control, March 2015, Springer Science + Business Media

    Dr Massimiliano Ruscica

  45. Risk identification and possible countermeasures for muscle adverse effects during statin therapy

    Article • European Journal of Internal Medicine, March 2015, Elsevier

    Dr Massimiliano Ruscica

  46. Changes in Stress Hormones and Metabolism During a 105-Day Simulated Mars Mission

    Article • Aviation Space and Environmental Medicine, August 2014, Aerospace Medical Association

    Dr Massimiliano Ruscica

  47. Hepatic steatosis and PNPLA3 I148M variant are associated with serum Fetuin-A independently of insulin resistance

    Article • European Journal of Clinical Investigation, June 2014, Wiley

    Luca Valenti, Dr Massimiliano Ruscica

  48. Statin therapy and related risk of new-onset type 2 diabetes mellitus

    Article • European Journal of Internal Medicine, June 2014, Elsevier

    Dr Massimiliano Ruscica

  49. Characterization and sub-cellular localization of SS1R, SS2R, and SS5R in human late-stage prostate cancer cells: Effect of mono- and bi-specific somatostatin analogs on cell growth

    Article • Molecular and Cellular Endocrinology, February 2014, Elsevier

    Dr Massimiliano Ruscica

  50. In VitroChronic Administration of ERbeta Selective Ligands and Prostate Cancer Cell Growth: Hypotheses on the Selective Role of 3beta-Adiol in AR-Positive RV1 Cells

    Article • BioMed Research International, January 2014, Hindawi Publishing Corporation

    Dr Massimiliano Ruscica

  51. Nutraceutical approach to moderate cardiometabolic risk: Results of a randomized, double-blind and crossover study with Armolipid Plus

    Article • Journal of Clinical Lipidology, January 2014, Elsevier

    Dr Massimiliano Ruscica

  52. Antiproliferative activity on human prostate carcinoma cell lines of new peptidomimetics containing the spiroazepinoindolinone scaffold

    Article • Bioorganic & Medicinal Chemistry, September 2013, Elsevier

    Dr Massimiliano Ruscica

  53. Dietary Iron Overload Induces Visceral Adipose Tissue Insulin Resistance

    Article • American Journal Of Pathology, June 2013, Elsevier

    Dr Massimiliano Ruscica

  54. Somatostatin, Somatostatin Analogs and Somatostatin Receptor Dynamics in the Biology of Cancer Progression

    Article • Current Molecular Medicine, April 2013, Bentham Science Publishers

    Dr Massimiliano Ruscica

  55. Low-intermediate dose testosterone replacement therapy by different pharmaceutical preparations improves frailty score in elderly hypogonadal hyperglycaemic patients

    Article • The Aging Male, March 2013, Taylor & Francis

    Dr Massimiliano Ruscica

  56. GC–MS profiling of the phytochemical constituents of the oleoresin from Copaifera langsdorffii Desf. and a preliminary in vivo evaluation of its antipsoriatic effect

    Article • International Journal of Pharmaceutics, January 2013, Elsevier

    Dr Fabrizio Gelmini, Dr Massimiliano Ruscica

  57. The i148m Pnpla3 polymorphism influences serum adiponectin in patients with fatty liver and healthy controls

    Article • BMC Gastroenterology, August 2012, Springer Science + Business Media

    Dr Massimiliano Ruscica

  58. Parthenolide Inhibits the LPS-induced Secretion of IL-6 and TNF-α and NF-κB Nuclear Translocation in BV-2 Microglia

    Article • Phytotherapy Research, February 2012, Wiley

    Dr Massimiliano Ruscica

  59. Impaired expression of insulin-like growth factor-1 system in skeletal muscle of amyotrophic lateral sclerosis patients

    Article • Muscle & Nerve, January 2012, Wiley

    Dr Massimiliano Ruscica

  60. Prognostic Effect of Circulating Adiponectin in a Randomized 2 × 2 Trial of Low-Dose Tamoxifen and Fenretinide in Premenopausal Women at Risk for Breast Cancer

    Article • Journal of Clinical Oncology, January 2012, American Society of Clinical Oncology (ASCO)

    Dr Massimiliano Ruscica

  61. Metabolic Syndrome, Adipokines and Hormonal Factors in Pharmacologically Untreated Adult Elderly Subjects from the Brisighella Heart Study Historical Cohort

    Article • Obesity Facts, January 2012, Karger Publishers

    Dr Arrigo FG CICERO, Dr Massimiliano Ruscica

  62. Adiponectin Interactions in Bone and Cartilage Biology and Disease

    Article • January 2012, Elsevier

    Dr Massimiliano Ruscica

  63. Corrigendum to “Regulation of prostate cancer cell proliferation by somatostatin receptor activation” [Mol. Cell. Endocrinol. 315 (1–2) (2010) 254–262]

    Article • Molecular and Cellular Endocrinology, July 2011, Elsevier

    Dr Massimiliano Ruscica

  64. Adipokines and Sexual Hormones Associated with the Components of the Metabolic Syndrome in Pharmacologically Untreated Subjects: Data from the Brisighella Heart Study

    Article • International Journal of Endocrinology, January 2011, Hindawi Publishing Corporation

    Dr Arrigo FG CICERO, Dr Massimiliano Ruscica

  65. Adipokine actions on cartilage homeostasis

    Article • January 2011, Elsevier

    Dr Massimiliano Ruscica

  66. Erratum to “The natural antioxidant alpha-lipoic acid induces p27Kip1-dependent cell cycle arrest and apoptosis in MCF-7 human breast cancer cells” [Eur. J. Pharmacol. 641 (2010) 29-34]

    Article • European Journal of Pharmacology, January 2011, Elsevier

    Dr Massimiliano Ruscica

  67. Somatostatin and dopamine receptor interaction in prostate and lung cancer cell lines

    Article • Journal of Endocrinology, September 2010, Bioscientifica

    Dr Massimiliano Ruscica

  68. The natural antioxidant alpha-lipoic acid induces p27Kip1-dependent cell cycle arrest and apoptosis in MCF-7 human breast cancer cells

    Article • European Journal of Pharmacology, September 2010, Elsevier

    Dr Massimiliano Ruscica

  69. Pharmacokinetics of orally administered melatonin in critically ill patients

    Article • Journal of Pineal Research, March 2010, Wiley

    Dr Massimiliano Ruscica

  70. Regulation of prostate cancer cell proliferation by somatostatin receptor activation

    Article • Molecular and Cellular Endocrinology, February 2010, Elsevier

    Dr Massimiliano Ruscica

  71. Leptin, Ciliary Neurotrophic Factor, Leukemia Inhibitory Factor and Interleukin- 6: Class-I Cytokines Involved in the Neuroendocrine Regulation of the Reproductive Function

    Article • Current Protein and Peptide Science, December 2009, Bentham Science Publishers

    Dr Massimiliano Ruscica

  72. Free insulin-like growth factor (IGF)-1 and IGF-binding proteins-2 and -3 in serum and cerebrospinal fluid of amyotrophic lateral sclerosis patients

    Article • European Journal of Neurology, October 2009, Wiley

    Dr Massimiliano Ruscica

  73. Feeding Behavior in Mammals Including Humans

    Article • Annals of the New York Academy of Sciences, April 2009, Wiley

    Dr Massimiliano Ruscica

  74. Effect of Fenretinide and Low-Dose Tamoxifen on Insulin Sensitivity in Premenopausal Women at High Risk for Breast Cancer

    Article • Cancer Research, November 2008, American Association for Cancer Research (AACR)

    Dr Massimiliano Ruscica

  75. Total, free and bound leptin and thyroid function in elderly women with different body weights

    Article • Clinical Endocrinology, June 2008, Wiley

    Dr Massimiliano Ruscica

  76. Cholinergic regulation of neuropeptide Y synthesis and release in human neuroblastoma cells

    Article • Peptides, March 2008, Elsevier

    Dr Massimiliano Ruscica

  77. Leukemia Inhibitory Factor Induces the Chemomigration of Immortalized Gonadotropin-Releasing Hormone Neurons through the Independent Activation of the Janus Kinase/Signal Transducer and Activator of Transcription 3, Mitogen-Activated Protein Kinase/Ext...

    Article • Molecular Endocrinology, May 2007, Endocrine Society

    Dr Massimiliano Ruscica

  78. A mutation and expression analysis of the oncogene BRAF in pituitary adenomas

    Article • Clinical Endocrinology, March 2007, Wiley

    Marta Korbonits, Dr Massimiliano Ruscica

  79. Role of neuropeptide Y and its receptors in the progression of endocrine-related cancer

    Article • Peptides, February 2007, Elsevier

    Dr Massimiliano Ruscica

  80. Hypothalamic Neuropeptide Systems as Targets for Potential Anti-Obesity Drugs

    Article • Mini-Reviews in Medicinal Chemistry, January 2007, Bentham Science Publishers

    Dr Massimiliano Ruscica

  81. Is ghrelin a signal of decreased fat-free mass in elderly subjects?

    Article • European Journal of Endocrinology, August 2006, Bioscientifica

    Dr Massimiliano Ruscica

  82. Activation of the Y1 Receptor by Neuropeptide Y Regulates the Growth of Prostate Cancer Cells

    Article • Endocrinology, March 2006, Endocrine Society

    Dr Massimiliano Ruscica

  83. Expression of Functional Ciliary Neurotrophic Factor Receptors in Immortalized Gonadotrophin-Releasing Hormone-Secreting Neurones

    Article • Journal of Neuroendocrinology, May 2005, Wiley

    Dr Massimiliano Ruscica

  84. Free and bound plasma leptin in normal weight and obese men and women: relationship with body composition, resting energy expenditure, insulin-sensitivity, lipid profile and macronutrient preference

    Article • Clinical Endocrinology, February 2005, Wiley

    Dr Massimiliano Ruscica

  85. Free and bound leptin in prepubertal children with Down's syndrome and different degrees of adiposity

    Article • European Journal of Clinical Nutrition, May 2004, Springer Science + Business Media

    Dr Massimiliano Ruscica

  86. Modulatory Actions of Neuropeptide Y on Prostate Cancer Growth: Role of MAP Kinase/ERK 1/2 Activatio

    Article • Springer Science + Business Media

    Dr Massimiliano Ruscica